Key facts for J1553
- Billing unit
- 100 MG
- Inj yimmugo 100 mg
- ASP payment limit
- $21.664
- October 2026; -10.3% vs July 2026
- Practitioner MUE
- none published
- CMS publishes no MUE for this code
- NCCI exposure
- no PTP pairs
- Coverage articles
- 3
- 14 states
TL;DR
HCPCS J1553 is the Level II code for Injection, immune globulin (yimmugo), 100 mg, billed per 100 MG. The Medicare Part B ASP payment limit for October 2026 is $21.664 per billing unit, down 10.3% from July 2026. Under OPPS it carries status indicator K in APC 0923. J1553 is billed in units of 100 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names immune globulin: J1551 (Cutaquig); J1555 (Cuvitru from Takeda Pharmaceuticals America, Inc); J1558 (Xembify from Grifols USA, LLC); J1559 (Hizentra from CSL Behring L.L.C); J1577 (Qivigy); J1552 (Alyglo from GC Biopharma USA, Inc.; billed per 500 mg). The ASP crosswalk maps 3 NDCs to it, sold as Yimmugo by Kedrion Biopharma Inc. 3 Medicare coverage articles list the code across 11 states plus DC and 2 territories, including A56786.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for J1553 at $21.664 per 100 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $24.145 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $21.664 | 100 MG | 20% |
| July 2026 | $24.145 | 100 MG | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 3 NDCs from 1 labeler to J1553. Report the NDC in the claim's drug segment and bill the number of J1553 units that equals the quantity administered divided by 100 MG; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 83372-0605-01 | Yimmugo | Kedrion Biopharma Inc | 50 × 1 | 50 |
| 83372-0605-11 | Yimmugo | Kedrion Biopharma Inc | 100 × 1 | 100 |
| 83372-0605-21 | Yimmugo | Kedrion Biopharma Inc | 200 × 1 | 200 |
Medically Unlikely Edits (MUE)
CMS does not publish an MUE for J1553 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.
MUE for J1553 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists J1553 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check J1553 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
J1553 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
3 current Medicare Administrative Contractor articles list J1553 in their HCPCS tables, covering 14 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.
| Article | Title | Contractor(s) | States | Related LCD |
|---|---|---|---|---|
| A56786 | Billing and Coding: Immune Globulin | Novitas Solutions, Inc. | DC DE MD NJ PA | L35093 |
| A57187 | Billing and Coding: Immune Globulin Intravenous (IVIg) | Noridian Healthcare Solutions, LLC | AZ MT ND SD UT WY | L34314 |
| A57778 | Billing and Coding: Immune Globulin | First Coast Service Options, Inc. | FL PR VI | L34007 |
Diagnoses Medicare contractors cover for J1553
3 billing and coding articles attach a covered diagnosis list to J1553: 150 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).
| ICD-10-CM | Description (FY2027) | Articles covering |
|---|---|---|
| C90.00 | Multiple myeloma not having achieved remission | 3 of 3 |
| C90.02 | Multiple myeloma in relapse | 3 of 3 |
| C91.10 | Chronic lymphocytic leukemia of B-cell type not having achieved remission | 3 of 3 |
| C91.12 | Chronic lymphocytic leukemia of B-cell type in relapse | 3 of 3 |
| D59.0 | Drug-induced autoimmune hemolytic anemia | 3 of 3 |
| D59.11 | Warm autoimmune hemolytic anemia | 3 of 3 |
| D59.12 | Cold autoimmune hemolytic anemia | 3 of 3 |
| D59.13 | Mixed type autoimmune hemolytic anemia | 3 of 3 |
| D59.19 | Other autoimmune hemolytic anemia | 3 of 3 |
| D69.3 | Immune thrombocytopenic purpura | 3 of 3 |
| D80.0 | Hereditary hypogammaglobulinemia | 3 of 3 |
| D80.1 | Nonfamilial hypogammaglobulinemia | 3 of 3 |
| D80.2 | Selective deficiency of immunoglobulin A [IgA] | 3 of 3 |
| D80.3 | Selective deficiency of immunoglobulin G [IgG] subclasses | 3 of 3 |
| D80.4 | Selective deficiency of immunoglobulin M [IgM] | 3 of 3 |
Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J1553 are counted here: a group whose instructions name J1553, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.
| Article | Contractor | Groups that apply | Covered codes for J1553 | Full list |
|---|---|---|---|---|
| A56786 | Novitas Solutions, Inc. | group 1 applies to J1553 | 108 | On LCD L35093 |
| A57187 | Noridian Healthcare Solutions, LLC | one list for every code in the article | 103 | On LCD L34314 |
| A57778 | First Coast Service Options, Inc. | group 1 applies to J1553 | 108 | On LCD L34007 |
Local coverage policies that list J1553
4 active Local Coverage Determinations list J1553 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.
- LCD L33610: Intravenous Immune Globulin · CGS Administrators, LLC; Noridian Healthcare Solutions, LLC
- Immune Globulin Intravenous (IVIg), LCD L34314 · Noridian Healthcare Solutions, LLC
- Immune Globulin (L35093) · Novitas Solutions, Inc.
- L34007 Immune Globulin · First Coast Service Options, Inc.
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, J1553 carries status indicator K and is assigned to APC 0923, with a published national unadjusted payment of $21.664. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), J1553 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $21.66 per 100 MG, paid only when the drug is furnished integral to a covered surgical procedure.
Common denials for J1553 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for J1553
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- 2026 HCPCS updates report: J1553 was added in the April 2026 HCPCS update.
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS J1553
What does HCPCS code J1553 describe?
J1553 is defined by CMS as "Injection, immune globulin (yimmugo), 100 mg". Each billing unit represents 100 MG, so the units reported on the claim must equal the dose administered divided by that unit.
Is J1553 a CPT code?
No. J1553 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as immune globulin (Yimmugo); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1553 reports the drug itself in 100 mg units, and the administration is billed on its own line.
What is the Medicare reimbursement for J1553 in October 2026?
The ASP-based payment limit is $21.664 per 100 MG, with 20% beneficiary coinsurance. The July 2026 limit was $24.145. Commercial payers use their own fee schedules.
Which NDCs map to J1553?
The October 2026 ASP crosswalk lists 3 NDCs from 1 labeler: Yimmugo (Kedrion Biopharma Inc). For example NDC 83372-0605-01 (package size 50) equals 50 billing units of J1553.
Does J1553 have NCCI bundling edits?
No active practitioner PTP pairs list J1553 as a column-1 or column-2 code in the v323r0 release.
J1553 vs J1551: what is the difference?
Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1551 apart: Cutaquig. J1553 is billed per 100 mg, limit $21.664; J1551 is billed per 100 mg, limit $14.172, MUE 1600. Report the code whose descriptor matches the product and setting in the record.
J1553 vs J1555: what is the difference?
Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1555 apart: Cuvitru from Takeda Pharmaceuticals America, Inc. J1553 is billed per 100 mg, limit $21.664; J1555 is billed per 100 mg, limit $17.994, MUE 480. Report the code whose descriptor matches the product and setting in the record.
Which Medicare coverage articles mention J1553?
3 current Billing and Coding Articles in the Medicare Coverage Database list J1553, covering 11 states plus DC and 2 territories: A56786 (Billing and Coding: Immune Globulin); A57187 (Billing and Coding: Immune Globulin Intravenous (IVIg)); A57778 (Billing and Coding: Immune Globulin).
What diagnosis codes support J1553?
3 Medicare billing and coding articles list 150 covered ICD-10-CM codes for J1553 between them, for example C90.00 (Multiple myeloma not having achieved remission); C90.02 (Multiple myeloma in relapse); C91.10 (Chronic lymphocytic leukemia of B-cell type not having achieved remission); C91.12 (Chronic lymphocytic leukemia of B-cell type in relapse); D59.0 (Drug-induced autoimmune hemolytic anemia). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.